



PRESS RELEASE

MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer

- **Management team strengthened as MaxiVAX develops ground-breaking Immuno-Oncology therapies**

Geneva, Switzerland – 03 February, 2016 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Dimitrios Goundis Ph.D., as its Chief Executive Officer. He joins the company after holding several senior management and R & D positions at The Medicines Company, Speedel and Roche, both in Europe and the US.

Prof. Bernard Mach, co-founder and chairman of MaxiVAX, commented: “We are delighted that Dimitrios is joining us as CEO. He has a very strong track record in biotech and pharma both in Europe and the US. As MaxiVAX is now in full-fledged clinical development, his experience and strength will benefit us immensely in securing business development opportunities, in leading our R&D programs and in managing relationships with investors. The company is making major progress in its clinical development programs, based on game-changing technologies, and consequently MaxiVAX is attracting recognition and interest from the cancer and life science communities.”

Dimitrios Goundis, Chief Executive Officer, said: “It is a privilege to be given the opportunity to lead MaxiVAX, which is backed by well-known figures in the industry. Cancer immunotherapy is one of the most dynamic therapeutic areas, targeted by many research institutes and life science companies. MaxiVAX has the potential to make a significant contribution to changing the standard of cancer care. We are building our core team of experts to ensure that the company’s potential is quickly optimised with appropriate clinical, regulatory and business development programs.”

Data is due to be announced shortly from the ground-breaking clinical Phase 1 trial of the company’s MVX-ONCO-1 cancer vaccine in 15 patients suffering from various cancers at an advanced stage, conducted at the Geneva University Hospitals under the auspices of SwissMedic.

Dimitrios Goundis biography

Dimitrios Goundis has over 25 years of experience in the life science sector. Since 2009 he worked for The Medicines Company (NASDAQ: MDCO) both in the US and in Europe, in various senior roles, including Business Development and Global Head of Research & Development. From 2000-2008 he was with Speedel in Basel, Switzerland, where he became Chief Operating Officer (COO). Prior to that he held senior project management and research scientist positions at F. Hoffman-La Roche in Basel, including immunology, oncology and the central nervous system. Dimitrios was awarded his PhD in Biochemistry from the University of Oxford, a BSc (Hons) in Chemistry and Biochemistry from the University of London, and a certificate in investment management from the London Business School.

About MVX-ONCO-1

MaxiVAX' novel Immuno-Oncology therapeutic vaccination is based on triggering the patient's own natural immune response mechanism via an innovative and proprietary technology in order to eliminate cancer cells. MVX-ONCO-1 has been classified as an Advanced Therapeutic Medicinal Product by the European Medicines Agency.

MVX-ONCO-1 consists of a two-component system:

1) Vaccine: administered by sub-cutaneous injection, using the patient's own irradiated cancer cells as vaccine antigens, with a key benefit of using the entire set of tumour antigens from the patient's own cells.

2) Immune boosting agent: an immune boosting agent (GM-CSF: granulocyte macrophage-colony stimulating factor) is delivered at the site of vaccination in a sustained manner, via genetically reprogrammed cells, encapsulated in a small hollow fibre capsule. The capsule, which is essential to protect the GM-CSF producing cells, is placed underneath the skin at the same site as the vaccine injection.

About MaxiVAX www.maxivax.ch

MaxiVAX is a Geneva-based clinical-stage biotech company developing the first active immunotherapy based on encapsulated cells for treating cancers. The field of Immuno-Oncology has recently seen successes of first generation cancer immunotherapies which are paving the way for MaxiVAX's novel and competitive approach. The company's mission is to develop novel therapeutic vaccines that are more effective, personalized, and enable the patient's immune system to fight his/her own disease.

The company is led by an experienced Board under the chairmanship of Prof. Bernard Mach, with a team of experts in clinical drug development and regulatory affairs. The Scientific & Clinical Advisory Group includes Prof. Patrick Aebischer, President of Ecole Polytechnique Federale Lausanne (EPFL), who pioneered the field of Encapsulation Cell Technology (used by MaxiVAX) and who has been an advisor to the company since its foundation.

The company is financed by private investors together with grants from public and private institutions.

Investor Contact

Prof. Bernard Mach: bernard.mach@unige.ch or Clarence Peter: cpeter@pplex.ch

MaxiVAX SA
Rue Bellot 6
CH-1206 Geneva
Switzerland
www.maxivax.ch

Media Contact

Nick Miles
Cabinet Privé de Conseils s.a.
Geneva, Switzerland
Phone : +41 22 321 45 40
Mobile : +41 79 678 76 26
E-mail : miles@cpc-pr.com

Edward Agne
The Communications Strategy Group Inc.
Cambridge, Mass, USA
Phone: +1 781 631 3117
Mobile: +1 781 888 0099
E-mail: edagne@comstratgroup.com